00 Token USD Price & Performance (00USD)

Virpax Pharmaceuticals has initiated a 1-for-25 reverse stock split to meet Nasdaq's $1.00 minimum bid price requirement. Effective March 20, 2025, the split will reduce shares from 31 million to 1.24 million. This move aims to maintain market listing and attract a broader investor base, though challenges remain.1

Cheche Group has regained compliance with Nasdaq's $1.00 minimum bid price requirement. The company achieved this milestone through organic price recovery, maintaining the threshold for 10 consecutive days. This development secures its listing status and enhances investor confidence, although sustaining long-term stability remains critical for the Chinese insurtech platform.2

Recent actions by Virpax and Cheche Group underscore the challenges of maintaining Nasdaq listing standards. Virpax's reverse split contrasts with Cheche's organic recovery. Both strategies reflect broader market pressures on small-cap companies to meet regulatory requirements while balancing investor expectations and operational goals.12